Torrent Pharmaceuticals announced Q4FY22 results: Revenue at Rs 2,131 crore up by 10% Gross margins: 71%; EBITDA margins: 29%. EBITDA at Rs 612 crore was down by 1%. Exceptional item of Rs 485 crore, relates to impairment provision and costs related to discontinuation of liquid business in the US. Commenting on the Q4 results, Samir Mehta, Chairman, said: “We are pleased with the robust operational performance delivered during the quarter. The branded businesses contributed to 70% of total revenues in Q4 and grew by 15% with India and Brazil continuing on a strong footing. The US business registered sequential growth aided mainly by launch of a new product. While our EU business faced some headwinds, we remain optimistic that the cost efficiency measures being taken will bring us back to growth in this market in the coming quarters. We have taken a difficult decision of discontinuing our liquids business in the US. We believe the incremental investments required will exceed the potential economic benefits in this segment due to changing market conditions, as economics and competitive intensity have turned unfavorable compared to the time of conceptualization.” Result PDF